NAMI-A

Cat. No.: HY-19376 CAS No.: 201653-76-1

Molecular Formula: C₅H₁₀Cl₄N₂ORuS.C₃H₄N₂.H

Molecular Weight: 458.18 Target: FAK

Pathway: Protein Tyrosine Kinase/RTK

-20°C Storage: Powder 3 years

> 4°C 2 years -80°C In solvent 6 months

> > -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

H₂O: 8.28 mg/mL (18.07 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1825 mL	10.9127 mL	21.8255 mL
	5 mM	0.4365 mL	2.1825 mL	4.3651 mL
	10 mM	0.2183 mL	1.0913 mL	2.1825 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 6.67 mg/mL (14.56 mM); Clear solution; Need ultrasonic and warming and heat to 60°C


BIOLOGICAL ACTIVITY

Description

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metalloproteinases MMP-2 and MMP-9 at micromolar concentrations. [1] The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases $\alpha 5\beta 1$ integrin expression and FAK auto-phosphorylation on Tyr 397. [2]In vivo: The reference for NAMI-A is 35 mg/kg/day. [1]

REFERENCES

[1]. Sava G et al. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res. 2003



Page 2 of 2 www.MedChemExpress.com